ArticleBreast cancer research and treatment2023
Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.
Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Accurate assessment of surgical HER2-low status based on core needle biopsy data of breast cancer.Diagnostic and prognostic research · 2026Article
- Added value of intravoxel incoherent motion histogram analysis in differentiating HER2-zero, HER2-low, and HER2-positive breast cancer.La Radiologia medica · 2026Article
- Intratumoral and peritumoral habitat imaging based on multiparametric MRI to predict HER2-negative breast cancer subtypes: a multicenter study.BMC medical imaging · 2026Article
- Integrating intratumoral and peritumoral radiomics with deep transfer learning from multiparametric MRI for preoperative prediction of HER2 status in breast cancer: a multicenter study.Frontiers in oncology · 2026Article
- HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.Biomedicines · 2025Review
- Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision.NPJ breast cancer · 2025Article
- Multimodal PA/US imaging and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers: A novel approach for targeted therapy selection.Photoacoustics · 2025Article
- Multiparametric MRI-based radiomics nomogram for noninvasive stratification of HER2 expression status in breast cancer.Quantitative imaging in medicine and surgery · 2025Article
- Reliability of core needle biopsy for HER2-low early-stage breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China.Breast cancer research : BCR · 2025Article
- Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.NPJ breast cancer · 2025Article
- Atypical Presentation of Metastatic Breast Cancer: Gastric Outlet Obstruction and Linitis Plastica.Cureus · 2025Article
- Intratumoral and peritumoral radiomics based on automated breast volume scanner for predicting human epidermal growth factor receptor 2 status.Frontiers in oncology · 2025Article
- Enhancing preoperative HER2 status classification of invasive breast cancers using machine learning models based on clinicopathological and MRI features: a multicenter study.Frontiers in cell and developmental biology · 2025Article
- Preoperatively predicting human epidermal growth factor receptor 2-low expression in breast cancer using neural network model based on multiparameter magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2024Article
- Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study.Breast cancer research : BCR · 2024Article
- Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.Breast cancer (Tokyo, Japan) · 2024Article
- Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.ESMO open · 2024Review
- Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?Annals of surgical oncology · 2024Article
- Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.Galen medical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe status of human epidermal growth factor receptor 2 (HER2) is important for treatment decision-making of breast cancer and was commonly determined by core needle biopsy (CNB). The concordance of CNB with surgical excision biopsy (SEB) has been verified, but remain unclear according to the newly developed classification of HER2 status. Our study aimed to re-evaluate the diagnostic value of CNB for determining HER2 status in breast cancer, especially in the HER2-low population.
methodsEligible breast cancer patients in West China Hospital between January 1, 2007 and December 31, 2021 were enrolled consecutively and data were extracted from the Hospital Information System. The agreement of HER2 status between CNB and SEB was calculated by concordance rate and κ statistics, as well as the sensitivity, specificity, positive, and negative predictive values (PPV & NPV). Logistic models were used to explore potential factors associated with the discordance between both tests.
resultsOf 1829 eligible patients, 1097 (60.0%) and 1358 (74.2%) were consistent between CNB and SEB by pathological and clinical classifications, respectively, with κ value being 0.46 (0.43-0.49) and 0.57 (0.53-0.60). The sensitivity (50.9%-52.7%) and PPV (50.5%-55.2%) of CNB were especially low among IHC 1+ and 2+/ISH - subgroups by pathological classifications; however, it showed the highest sensitivity (77.5%) and the lowest specificity (73.9%) in HER2-low population by clinical classifications. Advanced N stages might be a stable indicator for the discordance between both tests.
conclusionThe diagnostic value of CNB was limited for determining HER2 status in breast cancer, especially in HER2-low population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.